ArticleDermatology online journal2025
Microcystic lymphangioma of the vulva.
Article in Dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic cutaneous lymphatic malformations are developmental anomalies of the lymphatic system characterized by lymphatic vessel dilatation. Microcystic forms, also known as circumscribed lymphangiomas, present as clusters of translucent or hemorrhagic vesicles, papules, or infiltrated plaques, often appearing in early childhood and primarily affecting the proximal extremities. Although generally asymptomatic, they may cause inflammatory, infectious, or hemorrhagic episodes. We report a 39-year-old woman with a 2-year history of vesicular lesions on the medial surface of both labia majora associated with intermittent pruritus and fluid leakage. Clinical examination revealed bilateral painless swellings, each approximately 6 cm, with translucent and hemorrhagic vesicles. Histology confirmed bilateral subcutaneous microcystic lymphangiomas. Given their benign nature, no treatment was recommended aside from surveillance. Microcystic lymphangiomas have an unpredictable course, with some remaining stable and others developing complications requiring treatment. Management depends on lesion location, symptoms, and esthetic impact, with options including sclerotherapy, CO₂ laser, or surgical excision, if necessary. This case highlights the importance of accurate diagnosis and individualized treatment of microcystic lymphangiomas.
Indexed as
Identifiers
41725484What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.